{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21","upperLimit":"232","value":"96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is alive and free from progression, per the modified International Myeloma Working Group Uniform Response Criteria, defined as any of:\n\n* Serum monoclonal protein ≥ 125% baseline and/or ≥ +0.5 g/dL from baseline,\n* Urine monoclonal protein ≥ 125% baseline and/or ≥ +200 mg/24 hour from baseline\n* New or increased bone lesions or plasmacytomas\n* Serum calcium \\> 11.5 mg/dL (attributed to increased plasma cells)","dispersionType":"Full Range","groups":[{"description":"Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.\n\nConcurrent therapeutic medications:\n\n* Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14\n* Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)\n\nOther drugs:\n\n* Aspirin: 81 or 325 mg daily oral\n* Pegfilgrastim subcutaneous on Day 2","id":"OG000","title":"Amrubicin + Lenalidomide + Dexamethasone"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"9 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"days"}